Product information and disease descriptionProduct descriptionProduct information
Co-prescribed/Concomitant therapies
3 evidence topics · 3 sources
Crizotinib supplied by Pfizer for the combination trials
Concomitant medications excluded in the OptimUM-02 trial: CYP3A4/5, P-gp and BCRP substrates, and QT-prolonging drugs
Antihypertensive and other blood pressure-lowering medications in the single-agent LXS196 study
“Active management of symptomatic hypotension was recommended per protocol and regular vital signs (including blood pressure and heart rate) and ECG monitoring were required throughout the study at regular study visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Investigators were encouraged to temporarily withhold concomitant medications that may cause hypotension prior to the first dose of LXS196 and implement more frequent blood pressure monitoring throughout the study as deemed necessary per clinical need.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antidiarrheal prophylaxis with the darovasertib and crizotinib combination
No evidence found.